|
Business Combinations (Tables)
|
12 Months Ended |
|
Sep. 28, 2013
|
|
Gen-Probe Incorporated [Member]
|
|
| Purchase Price Consideration |
The purchase
price consideration was as follows:
|
|
|
|
|
|
Cash paid
|
|
$ |
3,967,866 |
|
|
Deferred payment
|
|
|
1,655 |
|
|
Fair value of stock options
exchanged
|
|
|
2,655 |
|
|
|
|
|
|
|
Total purchase
price
|
|
$ |
3,972,176 |
|
|
|
|
|
|
|
| Components of Purchase Price Allocation |
The final,
adjusted components of the purchase price allocation are as
follows:
|
|
|
|
|
|
Cash
|
|
$ |
205,463 |
|
|
Accounts
receivable
|
|
|
81,444 |
|
|
Inventory
|
|
|
153,416 |
|
|
Property, plant and
equipment
|
|
|
274,095 |
|
|
Other assets
|
|
|
191,971 |
|
|
Assets held-for-sale,
net
|
|
|
87,465 |
|
|
Accounts payable
|
|
|
(19,671 |
) |
|
Accrued expenses
|
|
|
(131,623 |
) |
|
Other
liabilities
|
|
|
(22,939 |
) |
|
Identifiable intangible
assets:
|
|
|
|
|
|
Developed
technology
|
|
|
1,700,000 |
|
|
In-process research and
development
|
|
|
117,000 |
|
|
Customer
contract
|
|
|
585,000 |
|
|
Trade names
|
|
|
95,000 |
|
|
Deferred income taxes,
net
|
|
|
(985,465 |
) |
|
Goodwill
|
|
|
1,641,020 |
|
|
|
|
|
|
|
Purchase Price
|
|
$ |
3,972,176 |
|
|
|
|
|
|
|
| Assets Groups Classified as Held for Sale |
The following
represents the components of the asset groups classified as
held-for-sale as of September 29, 2012:
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
Cash
|
|
$ |
2,563 |
|
|
Accounts
receivable
|
|
|
8,520 |
|
|
Inventory
|
|
|
15,680 |
|
|
Property, plant and
equipment
|
|
|
13,259 |
|
|
Other assets
|
|
|
3,083 |
|
|
Intangible assets and
goodwill
|
|
|
51,398 |
|
|
|
|
|
|
|
Total assets
held-for-sale
|
|
$ |
94,503 |
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
Accrued
liabilities
|
|
|
(7,622 |
) |
|
|
|
|
|
|
Net assets
held-for-sale
|
|
$ |
86,881 |
|
|
|
|
|
|
|
| Schedule of Unaudited Pro Forma Information |
The following
unaudited pro forma information presents the combined financial
results for the Company and Gen-Probe as if the acquisition of
Gen-Probe had been completed at the beginning of fiscal
2011:
|
|
|
|
|
|
|
|
|
| |
|
Year Ended
September 29, 2012 |
|
|
Year Ended
September 24, 2011 |
|
|
|
|
|
Revenue
|
|
$ |
2,526,336 |
|
|
$ |
2,310,384 |
|
|
Net loss
|
|
$ |
(164,539 |
) |
|
$ |
(127,240 |
) |
|
Basic and diluted net loss
per common share
|
|
$ |
(0.62 |
) |
|
$ |
(0.49 |
) |
|
|
TCT International Co., Ltd. [Member]
|
|
| Components of Purchase Price Allocation |
The components
of the purchase price allocation consisted of the
following:
|
|
|
|
|
|
Cash
|
|
$ |
27,961 |
|
|
Accounts
receivable
|
|
|
17,811 |
|
|
Inventory
|
|
|
5,301 |
|
|
Property and
equipment
|
|
|
4,710 |
|
|
Other tangible
assets
|
|
|
1,082 |
|
|
Accrued taxes
|
|
|
(14,874 |
) |
|
Accounts payable and
accrued expenses
|
|
|
(6,641 |
) |
|
Customer
relationships
|
|
|
45,780 |
|
|
Business
licenses
|
|
|
2,500 |
|
|
Trade names
|
|
|
2,110 |
|
|
Deferred taxes,
net
|
|
|
(12,473 |
) |
|
Goodwill
|
|
|
75,161 |
|
|
|
|
|
|
|
Purchase Price
|
|
$ |
148,428 |
|
|
|
|
|
|
|
|
Interlace Medical, Inc [Member]
|
|
| Purchase Price Consideration |
The purchase
price consideration was as follows:
|
|
|
|
|
|
Cash
|
|
$ |
126,798 |
|
|
Contingent
consideration
|
|
|
86,600 |
|
|
|
|
|
|
|
Total purchase
price
|
|
$ |
213,398 |
|
|
|
|
|
|
|
| Components of Purchase Price Allocation |
The components
of the purchase price allocation consisted of the
following:
|
|
|
|
|
|
Cash
|
|
$ |
9,070 |
|
|
Inventory, including fair
value adjustments
|
|
|
1,795 |
|
|
Other tangible
assets
|
|
|
1,291 |
|
|
Accounts payable and
accrued expenses
|
|
|
(1,988 |
) |
|
Developed
technology
|
|
|
158,741 |
|
|
Trade names
|
|
|
1,750 |
|
|
Deferred taxes,
net
|
|
|
(45,342 |
) |
|
Goodwill
|
|
|
88,081 |
|
|
|
|
|
|
|
Purchase Price
|
|
$ |
213,398 |
|
|
|
|
|
|
|